242 related articles for article (PubMed ID: 35102484)
1. Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.
Courand PY; Berger M; Bouali A; Harbaoui B; Lantelme P; Dalle S
Curr Oncol Rep; 2022 Mar; 24(3):265-271. PubMed ID: 35102484
[TBL] [Abstract][Full Text] [Related]
2. A Japanese case of melanoma of unknown origin with a rare BRAF
Kuriyama H; Kimura T; Mizuhashi S; Nishimura Y; Kanemaru H; Kajihara I; Makino K; Aoi J; Matsui H; Fukushima S
Drug Discov Ther; 2022 Nov; 16(5):256-257. PubMed ID: 36273892
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
4. Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.
Carbonnel F; Routier E; Lazure T; Mussini C; Bellanger C; Merklen C; Bejou B; Buisson A; Amiot A; Meyer A; Dong C; Robert C
Aliment Pharmacol Ther; 2023 Apr; 57(7):792-799. PubMed ID: 36578099
[TBL] [Abstract][Full Text] [Related]
5. BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma.
Carrabba NV; Siliezar PD; Laylani N; Lee AG
Can J Ophthalmol; 2023 Dec; 58(6):e251-e253. PubMed ID: 37545048
[No Abstract] [Full Text] [Related]
6. Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma.
Marani A; Gioacchini H; Paolinelli M; Offidani A; Campanati A
Expert Opin Drug Metab Toxicol; 2023; 19(8):555-567. PubMed ID: 37659065
[TBL] [Abstract][Full Text] [Related]
7. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
8. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
[No Abstract] [Full Text] [Related]
9. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of BRAF-mutated metastatic melanoma].
Boyles TB; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
12. [BRAF inhibitor and MEK inhibitor].
Uhara H
Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
[No Abstract] [Full Text] [Related]
13. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting.
Pedersen S; Larsen KO; Christensen AH; Svane IM; Zerahn B; Ellebaek E
Acta Oncol; 2022 Jan; 61(1):45-51. PubMed ID: 34666597
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.
Mukai K; Kamata M; Miyazaki M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Ishikawa T; Ohnishi T; Tada Y; Tanaka T
J Dermatol; 2021 May; 48(5):707-709. PubMed ID: 33600004
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.
Berger M; Amini-Adlé M; Maucort-Boulch D; Robinson P; Thomas L; Dalle S; Courand PY
Cancer Med; 2020 Apr; 9(8):2611-2620. PubMed ID: 32056395
[TBL] [Abstract][Full Text] [Related]
17. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
18. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
19. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma.
Demarez B; Eté M; David L; Quiles N; Archier E
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e688-e689. PubMed ID: 35398936
[No Abstract] [Full Text] [Related]
20. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
Goodman RS; Di Guardo L; Maurichi A; Kirwin B; Khattak A; Vanella V; Lee J; Lawless A; Czapla J; Spagnoletti A; Ambrosini M; Livingstone E; Long GV; Sullivan RJ; Carlino MS; Atkinson V; Trojanello C; Ascierto PA; Schadendorf D; Warburton L; Menzies AM; Santinami M; Johnson DB
Eur J Cancer; 2023 Nov; 194():113354. PubMed ID: 37827067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
